Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating ...

Exelixis, Inc. and Natera , a global leader in cell-free DNA and precision medicine, today announced their collaboration on the planned Exelixis-sponsored STELLAR-316 trial. This randomized phase 3 ...

Parts Cleaner and Degreaser is put to the test in this video featuring @CRCAutoUS. Discover its performance and effectiveness in automotive cleaning applications. The video covers detailed evaluations ...

California Resources Corporation (NYSE:CRC) is one of the Undervalued Stocks with Biggest Upside Potential. On December 12, Josh Silverstein from UBS reiterated a Buy rating on the stock but lowered ...

Reddit is starting a limited test of verified profiles, which places a grey checkmark beside the username of a notable person or business. “This feature is designed to help redditors understand who ...

A novel, blood-based test developed using fragmentomic features of cell-free DNA (cfDNA) detects colorectal cancer (CRC) with a 90.4% sensitivity and shows consistent performance across stages and ...

Advanced in organs on chips, digital twins, and AI are ushering in a new era of research and drug development. Earlier this week, the UK’s science minister announced an ambitious plan: to phase out ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new real-world data published in Current Medical Research and Opinion finding that the Shield blood-based ...

President Donald Trump on Thursday vowed to begin testing US nuclear weapons “on an equal basis” with Russia and China, heralding a potentially major shift in decades of US policy at a time of growing ...

Though the country’s nuclear arsenal has undergone no explosive testing for decades, federal experts say it can reliably obliterate targets halfway around the globe. By William J. Broad President ...

Introduction: Gastrointestinal (GI) cancers present significant clinical challenges characterized by dismal survival outcomes and suboptimal prognoses. Currently, only partial indicators are available ...

The FDA approved the Shield blood test for colorectal cancer (CRC) screening in adults ages 45 and older at average risk for the disease, Guardant Health announced. According to the company, the ...